肿瘤(癌症)患者之家
首页
癌症知识
肿瘤中医药治疗
肿瘤药膳
肿瘤治疗技术
前沿资讯
登录/注册
VIP特权

文章目录

通过配对末端测序(MPseq)表征儿童B淋巴母细胞白血病/淋巴瘤中的TCF3重排,发现复杂的基因组重排及一种新型TCF3/TEF基因融合

Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion

原文发布日期:2019-10-01

DOI: 10.1038/s41408-019-0239-z

类型: Article

开放获取: 是

英文摘要:

摘要翻译: 

原文链接:

文章:

通过配对末端测序(MPseq)表征儿童B淋巴母细胞白血病/淋巴瘤中的TCF3重排,发现复杂的基因组重排及一种新型TCF3/TEF基因融合

Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion

原文发布日期:2019-10-01

DOI: 10.1038/s41408-019-0239-z

类型: Article

开放获取: 是

 

英文摘要:

The TCF3/PBX1 gene fusion is a recurrent genetic abnormality in pediatric B-lymphoblastic leukemia/lymphoma (B-ALL/LBL). While dual-color, dual-fusion fluorescence in situ hybridization (D-FISH) probes can detect TCF3/PBX1 fusions, further characterization of atypical TCF3 FISH patterns as indicated by additional or diminished TCF3 signals is currently limited. Herein we describe the use of a next-generation sequencing assay, mate-pair sequencing (MPseq), to characterize typical and cryptic TCF3/PBX1 fusions and to identify TCF3 translocation partners based on results obtained from our laboratory-developed TCF3/PBX1 D-FISH probe set. MPseq was performed on 21 cases of pediatric B-ALL/LBL with either TCF3/PBX1 fusion, or no TCF3/PBX1 fusion but with additional or diminished TCF3 signals obtained by our PBX1/TCF3 D-FISH probe set. In addition, MPseq was performed on one pediatric B-ALL/LBL case with an apparently normal karyotype and abnormal TCF3 break-apart probe results. Of 22 specimens successfully evaluated by MPseq, 13 cases (59%) demonstrated TCF3/PBX1 fusion, including three cases with previously undescribed insertional rearrangements. The remaining nine cases (41%) harbored various TCF3 partners, including six cases with TCF3/ZNF384, and one case each with TCF3/HLF, TCF3/FLI1 and TCF3/TEF. Our results illustrate the power of MPseq to characterize TCF3 rearrangements with increased precision and accuracy over traditional cytogenetic methodologies.
 

摘要翻译: 

TCF3/PBX1基因融合是儿童B淋巴母细胞白血病/淋巴瘤(B-ALL/LBL)中常见的遗传学异常。虽然双色双融合荧光原位杂交(D-FISH)探针可检测TCF3/PBX1融合,但对TCF3信号增强或减弱所提示的非典型TCF3 FISH模式的进一步表征目前仍有限。本研究采用新一代测序技术——配对末端测序(MPseq),基于实验室自主研发的TCF3/PBX1 D-FISH探针组的检测结果,对典型性和隐匿性TCF3/PBX1融合进行表征,并鉴定TCF3易位伙伴。我们对21例儿童B-ALL/LBL样本进行MPseq分析,这些病例通过PBX1/TCF3 D-FISH探针组检测显示存在TCF3/PBX1融合,或无TCF3/PBX1融合但出现TCF3信号增强/减弱。此外,对1例核型显似正常但TCF3分离探针检测异常的儿童B-ALL/LBL病例也进行了MPseq分析。在成功完成MPseq检测的22例样本中,13例(59%)存在TCF3/PBX1融合,其中3例为既往未报道的插入性重排;其余9例(41%)涉及多种TCF3伙伴基因,包括6例TCF3/ZNF384融合,TCF3/HLF、TCF3/FLI1和TCF3/TEF融合各1例。我们的研究结果证明了MPseq在解析TCF3重排方面较传统细胞遗传学方法具有更高的精确度和准确性。

 

原文链接:

Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion

相关文章

文章:肿瘤抗原优先来源于黑色素瘤和非小细胞肺癌中未突变的基因组序列
文章:年龄相关的烟酰胺腺嘌呤二核苷酸下降驱动CAR-T细胞衰竭
文章:MCSP+转移创始细胞在人类黑色素瘤转移定植早期激活免疫抑制
文章:脂质纳米颗粒递送合成抗原使实体瘤对car介导的细胞毒性敏感
文章:食管癌新辅助治疗中的进化和免疫微环境动力学
文章:CHD1缺失重编程srebp2驱动的胆固醇合成,在spop突变的前列腺肿瘤中促进雄激素响应性生长和去势抵抗
文章:对TIL细胞治疗无反应的转移性非小细胞肺癌患者的T细胞和新抗原保留受损的时间序列分析
文章:策展的癌细胞图谱提供了单细胞分辨率的肿瘤的全面表征
文章:以人群为基础的胶质瘤分子景观分析在青少年和年轻人揭示胶质瘤形成的见解
文章:肿瘤细胞上的PILRα与T细胞表面蛋白CD99相互作用抑制抗肿瘤免疫

……